Henlius Speeds Up Efforts On Ophthalmic Bevacizumab
Phase III Trial Begins As Chinese Firm Works With Partner Essex On Global Filings
Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.
You may also be interested in...
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.
Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.